Cargando…

Kinetics of hydrocortisone sodium phosphate penetration into the human aqueous humor after topical application

AIM OF THE STUDY: Hydrocortisone is a soft steroid with low anti‐inflammatory properties and a short duration of action, used to manage several ocular conditions. The clinical benefits and side effects associated with hydrocortisone are well documented, but its basic pharmacokinetic in the eye is ye...

Descripción completa

Detalles Bibliográficos
Autores principales: Cagini, Carlo, Muzi, Alessio, Castellucci, Greta, Ragna, Giulia, Lupidi, Marco, Alabed, Husam B. R., Pellegrino, Roberto Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286650/
https://www.ncbi.nlm.nih.gov/pubmed/34672064
http://dx.doi.org/10.1111/ijcp.14987
_version_ 1784748063281119232
author Cagini, Carlo
Muzi, Alessio
Castellucci, Greta
Ragna, Giulia
Lupidi, Marco
Alabed, Husam B. R.
Pellegrino, Roberto Maria
author_facet Cagini, Carlo
Muzi, Alessio
Castellucci, Greta
Ragna, Giulia
Lupidi, Marco
Alabed, Husam B. R.
Pellegrino, Roberto Maria
author_sort Cagini, Carlo
collection PubMed
description AIM OF THE STUDY: Hydrocortisone is a soft steroid with low anti‐inflammatory properties and a short duration of action, used to manage several ocular conditions. The clinical benefits and side effects associated with hydrocortisone are well documented, but its basic pharmacokinetic in the eye is yet to be fully elucidated. The purpose of this study is to investigate the anterior chamber penetration capabilities of hydrocortisone when used in different concentrations as eye drops treatment. MATERIALS AND METHODS: This is a double‐blind, single‐centre, randomised clinical trial performed at the Department of Medicine and Surgery of the University of Perugia (Italy) on consecutive patients who undergone phacoemulsification with intraocular lens implantation. Patients were randomly assigned on the morning of surgery to receive a single instillation of 0.33% (group A) or 0.001% (group B) hydrocortisone sodium phosphate solution. Group of patients C did not receive any treatment and was used to measure the hydrocortisone endogenous levels. Before surgery, one aliquot of aqueous humor for each patient was aspirated. The time of collection for each sample was recorded. Hydrocortisone concentrations were then stratified into six interval classes of 30 minutes each. RESULTS: The mean concentration of hydrocortisone was significantly higher in group A (25.2 ± 12.4 ng/mL) compared with group B (7.11 ± 1.51 ng/mL) and compared with the mean hydrocortisone endogenous levels (3.92 ± 1.18 ng/mL) (P < .0001). No statistically significant differences of hydrocortisone mean concentrations between group B and the mean endogenous levels were found. CONCLUSIONS: Considering the frequent need for prolonged topical steroid therapies and the possible consequent undesirable side effects, ophthalmologists should consider the lowest clinically effective dose of hydrocortisone useful to obtain the desired therapeutic effect and in an adequate time, to minimise the amount of steroids into the anterior chamber and to avoid side effects like intra‐ocular pressure increase or cataract development.
format Online
Article
Text
id pubmed-9286650
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92866502022-07-19 Kinetics of hydrocortisone sodium phosphate penetration into the human aqueous humor after topical application Cagini, Carlo Muzi, Alessio Castellucci, Greta Ragna, Giulia Lupidi, Marco Alabed, Husam B. R. Pellegrino, Roberto Maria Int J Clin Pract Short Reports AIM OF THE STUDY: Hydrocortisone is a soft steroid with low anti‐inflammatory properties and a short duration of action, used to manage several ocular conditions. The clinical benefits and side effects associated with hydrocortisone are well documented, but its basic pharmacokinetic in the eye is yet to be fully elucidated. The purpose of this study is to investigate the anterior chamber penetration capabilities of hydrocortisone when used in different concentrations as eye drops treatment. MATERIALS AND METHODS: This is a double‐blind, single‐centre, randomised clinical trial performed at the Department of Medicine and Surgery of the University of Perugia (Italy) on consecutive patients who undergone phacoemulsification with intraocular lens implantation. Patients were randomly assigned on the morning of surgery to receive a single instillation of 0.33% (group A) or 0.001% (group B) hydrocortisone sodium phosphate solution. Group of patients C did not receive any treatment and was used to measure the hydrocortisone endogenous levels. Before surgery, one aliquot of aqueous humor for each patient was aspirated. The time of collection for each sample was recorded. Hydrocortisone concentrations were then stratified into six interval classes of 30 minutes each. RESULTS: The mean concentration of hydrocortisone was significantly higher in group A (25.2 ± 12.4 ng/mL) compared with group B (7.11 ± 1.51 ng/mL) and compared with the mean hydrocortisone endogenous levels (3.92 ± 1.18 ng/mL) (P < .0001). No statistically significant differences of hydrocortisone mean concentrations between group B and the mean endogenous levels were found. CONCLUSIONS: Considering the frequent need for prolonged topical steroid therapies and the possible consequent undesirable side effects, ophthalmologists should consider the lowest clinically effective dose of hydrocortisone useful to obtain the desired therapeutic effect and in an adequate time, to minimise the amount of steroids into the anterior chamber and to avoid side effects like intra‐ocular pressure increase or cataract development. John Wiley and Sons Inc. 2021-10-26 2021-12 /pmc/articles/PMC9286650/ /pubmed/34672064 http://dx.doi.org/10.1111/ijcp.14987 Text en © 2021 The Authors. International Journal of Clinical Practice published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Short Reports
Cagini, Carlo
Muzi, Alessio
Castellucci, Greta
Ragna, Giulia
Lupidi, Marco
Alabed, Husam B. R.
Pellegrino, Roberto Maria
Kinetics of hydrocortisone sodium phosphate penetration into the human aqueous humor after topical application
title Kinetics of hydrocortisone sodium phosphate penetration into the human aqueous humor after topical application
title_full Kinetics of hydrocortisone sodium phosphate penetration into the human aqueous humor after topical application
title_fullStr Kinetics of hydrocortisone sodium phosphate penetration into the human aqueous humor after topical application
title_full_unstemmed Kinetics of hydrocortisone sodium phosphate penetration into the human aqueous humor after topical application
title_short Kinetics of hydrocortisone sodium phosphate penetration into the human aqueous humor after topical application
title_sort kinetics of hydrocortisone sodium phosphate penetration into the human aqueous humor after topical application
topic Short Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286650/
https://www.ncbi.nlm.nih.gov/pubmed/34672064
http://dx.doi.org/10.1111/ijcp.14987
work_keys_str_mv AT caginicarlo kineticsofhydrocortisonesodiumphosphatepenetrationintothehumanaqueoushumoraftertopicalapplication
AT muzialessio kineticsofhydrocortisonesodiumphosphatepenetrationintothehumanaqueoushumoraftertopicalapplication
AT castelluccigreta kineticsofhydrocortisonesodiumphosphatepenetrationintothehumanaqueoushumoraftertopicalapplication
AT ragnagiulia kineticsofhydrocortisonesodiumphosphatepenetrationintothehumanaqueoushumoraftertopicalapplication
AT lupidimarco kineticsofhydrocortisonesodiumphosphatepenetrationintothehumanaqueoushumoraftertopicalapplication
AT alabedhusambr kineticsofhydrocortisonesodiumphosphatepenetrationintothehumanaqueoushumoraftertopicalapplication
AT pellegrinorobertomaria kineticsofhydrocortisonesodiumphosphatepenetrationintothehumanaqueoushumoraftertopicalapplication